Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2).
Joseph Merriman
No relevant relationships to disclose
Kinjal Parikh
No relevant relationships to disclose
Srinivas Kiran Tantravahi
No relevant relationships to disclose
Alli M. Straubhar
No relevant relationships to disclose
Archana M. Agarwal
No relevant relationships to disclose
Arun Sendilnathan
No relevant relationships to disclose
Joan Van Atta
No relevant relationships to disclose
Julia A. Batten
No relevant relationships to disclose
Kenneth F. Grossmann
No relevant relationships to disclose
Wolfram E. Samlowski
No relevant relationships to disclose
David D. Stenehjem
No relevant relationships to disclose
Neeraj Agarwal
No relevant relationships to disclose